Who Generates More Revenue? United Therapeutics Corporation or Ionis Pharmaceuticals, Inc.

Biotech Revenue Showdown: United Therapeutics vs. Ionis

__timestampIonis Pharmaceuticals, Inc.United Therapeutics Corporation
Wednesday, January 1, 20142141610001288519000
Thursday, January 1, 20152837030001465761000
Friday, January 1, 20163466200001598800000
Sunday, January 1, 20175076660001725300000
Monday, January 1, 20185996740001627800000
Tuesday, January 1, 201911230000001448800000
Wednesday, January 1, 20207290000001483300000
Friday, January 1, 20218100000001685500000
Saturday, January 1, 20225870000001936300000
Sunday, January 1, 20237876470002327500000
Loading chart...

Cracking the code

Revenue Race: United Therapeutics vs. Ionis Pharmaceuticals

In the competitive landscape of biotechnology, revenue generation is a key indicator of a company's market strength and innovation prowess. Over the past decade, United Therapeutics Corporation has consistently outperformed Ionis Pharmaceuticals, Inc. in terms of revenue. From 2014 to 2023, United Therapeutics saw a robust growth trajectory, with revenue peaking at approximately $2.33 billion in 2023, marking an impressive 81% increase from 2014. In contrast, Ionis Pharmaceuticals, while showing growth, reached its highest revenue of around $1.12 billion in 2019, a significant 424% increase from its 2014 figures. Despite Ionis's rapid growth rate, United Therapeutics maintained a commanding lead, generating nearly double the revenue of Ionis in 2023. This data underscores United Therapeutics' strong market position and strategic advancements in the biotech sector, while Ionis continues to carve its niche with promising growth potential.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025